Immune Modulation by Exosomes in COVID-19

Recruiting now

Conditions studied: COVID-19, Critical Illness, Hypercytokinemia, Lung Fibrosis

In brief

Following whole blood stimulation with mesenchymal stem cell derived exosomes, immune phenotype, cytokine release and mRNA expression patterns from critically ill patients with COVID-19 will be determined.

Key facts

Study ID

NCT05191381

Run by

University of Ulm

People needed

40

Starts

2021-12-22

Expected to finish

2026-12-31

Last updated by the study team

2024-01-17

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Critically ill COVID-19 patients with lung dysfunction
• COVID-19 WHO severity degree >= 4, ARDS (WHO Definition 13 March 2020)
• Body weight > 50 kg
• Informed consent

You may not qualify if…

• Pregnant or breast feeding women

Where it is running

• Ulm University Hospital, Clinic of Anesthesiology and Intensive Care Medicine — Ulm, Germany (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.